No Prescription

No Prescription
HomeAlpha IndexCategories

Allergy

Anti Bacterial

Anti Convulsants

Anti Depressants

Anti Fungal

Anti Narcoleptic

Anti Viral

Antibiotics

Arthritis

Asthma

Birth Control

Blood Pressure

Cancer

Cardiovascular

Cholesterol

Diabetes

Diuretics

Eye Drops

Gastrointestinal

Hair Care

Herbal & Diet Supplements

Men's Health

Migraines

Muscle Relaxers

Nausea & Vomiting

Other

Pain Medicine

Pet Herbal Remedies

Prescription Drugs 1

Prescription Drugs 2

Prescription Drugs 3

Prescription Drugs 4

Prescription Drugs 5

Prescription Drugs 6

Prescription Drugs 7

Prescription Drugs 8

Prescription Drugs 9

Prescription Drugs 10

Prescription Drugs 11

Prescription Drugs 12

Prescription Drugs 13

Prescription Drugs 14

Prescription Drugs 15

Prescription Drugs 16

Prescription Drugs 17

Respiratory

Skin Care

Stop Smoking

Thyroid

Weight Loss

Women's Health

No Prescription

Alphabetical Index

Categories

TEGIBS Zelnorm

No Prescription » Prescription Drugs 15 » TEGIBS Zelnorm

Tegaserod is used to relieve pain bloating and constipation caused by irritable bowel syndrome (IBS; a condition that causes stomach pain bloating constipation and diarrhea) in women whose main symptom is constipation. This medication is also used to increase the frequency of bowel movements and relieve bloating straining and stomach pain in women and men with chronic idiopathic constipation (constipation that is not due to other diseases or medications and that has been a problem for longer than 6 months). Tegaserod is in a class of medications called serotonin agonists. It works by improving muscle movement and increasing production of fluid in the bowels.Tegaserod comes as a tablet to take by mouth. It is usually taken twice a day on an empty stomach shortly before a meal. Take tegaserod at around the same times every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take tegaserod exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.If you have IBS with constipation your doctor will probably tell you to take tegaserod for 4-6 weeks. If your symptoms improve your doctor may tell you to take tegaserod for another 4-6 weeks. If you have chronic idiopathic constipation you should talk to your doctor regularly to see if you should continue to take tegaserod. Be sure to tell your doctor how you are feeling and do not take tegaserod for longer than your doctor prescribes.Tegaserod controls the symptoms of irritable bowel syndrome and chronic idiopathic constipation but does not cure these conditions. Continue to take tegaserod even if you feel well. Do not stop taking tegaserod without talking to your doctor. If you stop taking tegaserod your symptoms may return within 1-2 weeks.

Buy TEGIBS Zelnorm and other Prescription Drugs 15 products online at Medstore.

Buy Online at Medstore - Click Here!

About TEGIBS Zelnorm:

Product Type: Prescription Drugs 15

TEGIBS ( Zelnorm Generic TEGASEROD )

TEGIBS (Zelnorm Generic TEGASEROD)

Zelnorm Generic TEGASEROD

6mg Zelnorm Generic TEGASEROD TEGIBS

View more Prescription Drugs 15

Previous Product  Next Product

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.